三磷酸腺苷与维拉帕米治疗室上性心动过速的疗效及安全性比较

The efficacy and safety of adenosine triphosphate and verapamil in the treatment of supraventricular tachycardia

目的对比观察三磷酸腺苷与维拉帕米治疗阵发性室上性心动过速患者的临床效果。方法将阵发性室上性心动过速患者80例随机分为观察组和对照组各40例。观察组予三磷酸腺苷治疗,对照组予维拉帕米治疗,对比2组转复成功率、室上性心动过速终止时间及不良反应发生情况。结果 2组转复成功率和不良反应发生率比较差异无统计学意义(P>0.05)。观察组室上性心动过速终止时间短于对照组(P<0.05)。结论三磷酸腺苷与维拉帕米治疗阵发性室上性心动过速患者的临床疗效均显著,且不良反应发生率较低,但三磷酸腺苷治疗的患者室上性心动过速终止时间明显缩短,值得推广应用。

Objective To comparison of the clinical efficacy of adenosine triphosphate and verapamil in the treatment of paroXysmal supraventricular tachycardia.Methods 80 cases with paroXysmal supraventricular tachycardia were randomly divided into observation group and control group,each group of 40 cases.The observation group was treated with adenosine triphosphate,the control group was treated with verapamil,compared the success rate of recurrence,the time of termination of supraventricular tachycardia,and the occurrence of adverse.Results There was no significant difference in the success rate and the incidence of adverse reactions between the two groups（P〉0.05）.The time of termination of supraventricular tachycardia in the observation group was shorter than that in the control group（P〈0.05）.Conclusion The clinical efficacy of adenosine triphosphate and verapamil in the treatment of paroXysmal supraventricular tachycardia is significant,and the incidence of adverse reactions is lower,but the treatment of adenosine triphosphate patients with supraventricular tachycardia termination time was significantly shorter,worthy of popularization and application.